Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib
Year: 2019
Type: conference-abstract
Source: Blood
Institutions: City Of Hope National Medical Center, Massachusetts General Hospital, UPMC Hillman Cancer Center, Huntsman Cancer Institute, University of Chicago Medical Center, Beth Israel Deaconess Medical Center, Moores Cancer Center, Juno Therapeutics (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2988085430